Aveanna Healthcare (NASDAQ:AVAH) Price Target Cut to $10.00 by Analysts at BMO Capital Markets

Aveanna Healthcare (NASDAQ:AVAH) had its target price decreased by equities researchers at BMO Capital Markets from $11.00 to $10.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. BMO Capital Markets’ target price points to a potential upside of 53.02% from the stock’s current price.

AVAH has been the subject of several other research reports. Raymond James Financial upgraded Aveanna Healthcare from an “outperform” rating to a “strong-buy” rating and set a $13.00 target price for the company in a research note on Friday. Truist Financial cut their price objective on shares of Aveanna Healthcare from $10.00 to $9.00 and set a “hold” rating on the stock in a report on Friday. Zacks Research downgraded shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Royal Bank Of Canada increased their target price on shares of Aveanna Healthcare from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Thursday, January 15th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Aveanna Healthcare in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Aveanna Healthcare has a consensus rating of “Moderate Buy” and a consensus price target of $10.81.

Aveanna Healthcare Stock Up 3.1%

NASDAQ AVAH traded up $0.20 during trading on Friday, reaching $6.54. 994,112 shares of the company’s stock were exchanged, compared to its average volume of 1,198,656. The company has a 50 day moving average price of $7.88 and a two-hundred day moving average price of $8.50. The stock has a market cap of $1.37 billion, a P/E ratio of 18.18 and a beta of 2.07. Aveanna Healthcare has a 1 year low of $3.73 and a 1 year high of $10.32. The company has a debt-to-equity ratio of 140.39, a quick ratio of 1.23 and a current ratio of 1.23.

Insider Buying and Selling at Aveanna Healthcare

In other Aveanna Healthcare news, insider Edwin C. Reisz sold 60,769 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total value of $438,144.49. Following the completion of the transaction, the insider owned 1,447,057 shares in the company, valued at approximately $10,433,280.97. This represents a 4.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jeff Shaner sold 173,225 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $7.21, for a total transaction of $1,248,952.25. Following the completion of the sale, the chief executive officer owned 2,650,892 shares of the company’s stock, valued at $19,112,931.32. This trade represents a 6.13% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 998,595 shares of company stock valued at $7,567,770. Corporate insiders own 7.80% of the company’s stock.

Institutional Investors Weigh In On Aveanna Healthcare

A number of large investors have recently added to or reduced their stakes in AVAH. Caitong International Asset Management Co. Ltd raised its holdings in Aveanna Healthcare by 252.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock valued at $27,000 after buying an additional 2,400 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Aveanna Healthcare in the second quarter worth $43,000. Oxford Asset Management LLP purchased a new position in shares of Aveanna Healthcare in the 2nd quarter valued at $64,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Aveanna Healthcare in the 2nd quarter valued at $68,000. Finally, PharVision Advisers LLC acquired a new position in shares of Aveanna Healthcare during the 2nd quarter valued at $78,000. 87.96% of the stock is owned by institutional investors and hedge funds.

Aveanna Healthcare News Roundup

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Q4 results materially beat estimates — Aveanna reported revenue of $662.5M (up ~27% YoY) and an EPS beat (reported $0.83 vs. consensus near $0.13). The strong top‑line growth and big EPS beat are the main bullish catalysts. GlobeNewswire Q4 Results
• Positive Sentiment: Raymond James upgraded AVAH from Outperform to Strong‑Buy and set a $13 price target (~~97% above the recent price), which likely boosted investor demand and sentiment. Finviz (Raymond James Upgrade)
• Neutral Sentiment: Earnings call / transcripts available for detail — Investors can review management’s commentary on margins, organic growth and reimbursement trends in the Q4 call transcript to assess sustainability of recent results. Earnings Call Transcript
• Neutral Sentiment: Short‑interest data in recent reports appears unreliable/zeroed out (reported as 0 shares), so it doesn’t provide a clear signal on positioning or potential squeezes at the moment.
• Negative Sentiment: Fiscal‑2026 revenue/growth outlook disappointed some analysts and investors — coverage noted that the company’s revenue outlook trailed consensus, which pressured the stock despite the Q4 beat. That guidance miss is the main bearish offset to today’s gains. MSN (Guidance Miss)
• Negative Sentiment: Some outlets flagged the fiscal‑2026 guidance update as a reason for intracday weakness after the initial pop, highlighting that near‑term growth assumptions and reimbursement dynamics will be key watchpoints for investors. TipRanks (Guidance & Outlook)

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.